- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Novel Anthracycline Utorubicin for Cancer Therapy ; day:01 ; month:06 ; year:2021 ; extent:12
Angewandte Chemie ; (01.06.2021) (gesamt 12)
- Creator
-
Simón‐Gracia, Lorena
Sidorenko, Valeria
Uustare, Ain
Ogibalov, Ivan
Tasa, Andrus
Tshubrik, Olga
Teesalu, Tambet
- DOI
-
10.1002/ange.202016421
- URN
-
urn:nbn:de:101:1-2021060215080156077205
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Simón‐Gracia, Lorena
- Sidorenko, Valeria
- Uustare, Ain
- Ogibalov, Ivan
- Tasa, Andrus
- Tshubrik, Olga
- Teesalu, Tambet
Other Objects (12)
Novel Anthracycline Utorubicin for Cancer Therapy
Juvenile competitive triathlete after cardiotoxic anthracycline therapy for Acute Myeloid Leukemia
Cardioprotection strategies for anthracycline cardiotoxicity
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Anthracycline therapy induces an early decline of cardiac contractility in low-risk patients with breast cancer
Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer
Anthracycline Chemotherapy and Cardiotoxicity
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
Novel Anthracycline Utorubicin for Cancer Therapy
Juvenile competitive triathlete after cardiotoxic anthracycline therapy for Acute Myeloid Leukemia
Cardioprotection strategies for anthracycline cardiotoxicity
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Anthracycline therapy induces an early decline of cardiac contractility in low-risk patients with breast cancer
Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer
Anthracycline Chemotherapy and Cardiotoxicity
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
Novel Anthracycline Utorubicin for Cancer Therapy
Juvenile competitive triathlete after cardiotoxic anthracycline therapy for Acute Myeloid Leukemia
Cardioprotection strategies for anthracycline cardiotoxicity
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Anthracycline therapy induces an early decline of cardiac contractility in low-risk patients with breast cancer
Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer
Anthracycline Chemotherapy and Cardiotoxicity
Novel strategies for cancer immunotherapy: counter-immunoediting therapy